OTCMKTS:GNWSF StageZero Life Sciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding StageZero Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.06 0.00 (0.00%) (As of 06/30/2022 12:00 AM ET) Add Compare Share Today's Range$0.06▼$0.0650-Day Range$0.06▼$0.0952-Week Range$0.00▼$1.27Volume1,000 shsAverage Volume26,719 shsMarket Capitalization$4.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNWSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GNWSF Stock Forecast (MarketRank)Overall MarketRank™0.91 out of 5 starsAnalyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for StageZero Life Sciences. Previous Next 4.5 Community Rank Outperform VotesStageZero Life Sciences has received 71 “outperform” votes. (Add your “outperform” vote.)Underperform VotesStageZero Life Sciences has received 32 “underperform” votes. (Add your “underperform” vote.)Community SentimentStageZero Life Sciences has received 68.93% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about StageZero Life Sciences and other stocks. Vote “Outperform” if you believe GNWSF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNWSF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldStageZero Life Sciences does not currently pay a dividend.Dividend GrowthStageZero Life Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, StageZero Life Sciences insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.02% of the stock of StageZero Life Sciences is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of StageZero Life Sciences is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of StageZero Life Sciences is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About StageZero Life Sciences (OTCMKTS:GNWSF)StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.Read More GNWSF Stock News HeadlinesJune 28, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Announces Results on Resolutions at Annual and Special MeetingMay 26, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Announces Resignation of CFOMay 26, 2022 | apnews.comStageZero Life Sciences Announces Resignation of CFOMay 25, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Partners with DiagnoseAtHome to Offer Aristotle Multi-Cancer Blood Test in Canada and USAMay 17, 2022 | seekingalpha.comStageZero Life Sciences Ltd. (SZLSF) CEO James Howard-Tripp on Q1 2022 Results - Earnings Call TranscriptMay 15, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Launches COC Plus WorldwideMay 13, 2022 | baystreet.caStageZero Life SciencesMay 13, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero to Issue Q1 2022 Financial Results and Hold Conference Call on Tuesday May 17March 29, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Friday April 1March 3, 2022 | finanznachrichten.deStageZero Life Sciences Ltd.: StageZero Life Sciences Announces Closing of CAD$1.87 Million Private Placement with Institutional InvestorFebruary 28, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Announces CAD$1.87 Million Private Placement with Institutional InvestorDecember 14, 2021 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Announces Formation of Scientific Advisory BoardDecember 13, 2021 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences Named a COVID-19 Travel Testing Partner for ArubaSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GNWSF CUSIPN/A CIK1454263 Webwww.stagezerolifesciences.com Phone905-209-2030FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6.86 million Net Margins-200.26% Pretax MarginN/A Return on EquityN/A Return on Assets-165.13% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.08 Sales & Book Value Annual Sales$4.15 million Price / Sales0.96 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-3.17Miscellaneous Outstanding Shares62,995,000Free FloatN/AMarket Cap$4.00 million OptionableNot Optionable Beta0.28 StageZero Life Sciences Frequently Asked Questions How has StageZero Life Sciences' stock price performed in 2022? StageZero Life Sciences' stock was trading at $0.2303 at the beginning of 2022. Since then, GNWSF stock has decreased by 72.4% and is now trading at $0.063450. View the best growth stocks for 2022 here. Who are StageZero Life Sciences' key executives? StageZero Life Sciences' management team includes the following people: Mr. James R. Howard-Tripp, Exec. Chairman & CEOMr. Carl Solomon, Interim Chief Financial OfficerProf. Choong-Chin Liew, Co-FounderMr. Warren Whitehead C.M.A., Chief Accountant (Age 69)Mr. David Suria, Sr. Scientist Who are some of StageZero Life Sciences' key competitors? Some companies that are related to StageZero Life Sciences include StageZero Life Sciences (SZLSF), StageZero Life Sciences (GNWSD), Global WholeHealth Partners (GWHP), FluoroPharma Medical (FPMI), BG Medicine (BGMD), Hemagen Diagnostics (HMGN) and Response Genetics (RGDXQ). View all of GNWSF's competitors. What is StageZero Life Sciences' stock symbol? StageZero Life Sciences trades on the OTCMKTS under the ticker symbol "GNWSF." How do I buy shares of StageZero Life Sciences? Shares of GNWSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is StageZero Life Sciences' stock price today? One share of GNWSF stock can currently be purchased for approximately $0.06. How much money does StageZero Life Sciences make? StageZero Life Sciences (OTCMKTS:GNWSF) has a market capitalization of $4.00 million and generates $4.15 million in revenue each year. How many employees does StageZero Life Sciences have? StageZero Life Sciences employs 51 workers across the globe. How can I contact StageZero Life Sciences? StageZero Life Sciences' mailing address is 70 East Beaver Creek Road Unit 30, Richmond Hill A6, L4B 3B2. The official website for StageZero Life Sciences is www.stagezerolifesciences.com. The company can be reached via phone at 905-209-2030 or via email at [email protected]. This page (OTCMKTS:GNWSF) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here